AgomAb Therapeutics NV (AGMB) Stock Forecast: StockMap's 2-Week Call
AGMB stock forecast: StockMap's model leans Underperform on AgomAb Therapeutics NV for the two weeks after the Nov 19 close, toward AGMB trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on AGMB since Aug 21; by chance, a call on the same dates was right 58% of the time.
AgomAb Therapeutics NV last closed at $5.62, -3.44% on the session.
Against the IVW growth benchmark the position is -1.11% over the forecast window.
AgomAb Therapeutics NV's market cap is $276.76M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where AGMB sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
46 daily calls for AGMB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
AgomAb Therapeutics NV is classified under Health Care / Pharmaceuticals.
StockMap tracks AgomAb Therapeutics NV as the 87th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite AgomAb Therapeutics NV ranks 86th of 153 in the group, against a group median of -0.36.